As a consequence the probability for making decisions according to the myopic rule decreases according to an exponential decay as the training phase progresses and finally approaches 0. See Section 5.6.2 for a detailed discussion of the exponential decay parameter δ, biasing the decision making process.
PCNA localization patterns change as S phase progresses permitting the discrimination of early, middle and late S-phase stages[16], [37].
The frequency of spiking increases as the spiking phase progresses, and controls whether (h_{s}) increases or decreases.
In the transformation phase, as the growth phase progresses, the total thickness of the multilayer microcrystal increases and starts to replicate, creating a new complex from the crystal.
The probability decreases exponentially as the training phase progresses, but still proportionally less weight will be put on the current strategy during the first phase.
The probability for applying the current dispatching strategy is exponentially decreasing as the training phase progresses and will be applied with probability e− δn, where δ ⩾ 0 and n denotes the current iteration counter.
Therefore, in PHEMA-based ASD systems, as the swelling phase progresses, the amorphous drug entrapped in the PHEMA hydrogel will be first converted into supersaturated solution and then released by diffusion into the dissolution medium.
Remarkably, molecular functions and FFs withered as the phase progressed and in preparation of a truly diversified world of organisms approaches.
As S phase progressed, ORC1 dissociated and was degraded, while the levels of ORC2 5 decreased in the DNAse I-resistant and increased in DNAse I-sensitive fractions of the chromatin.
During the postshift phase, there was a strong interaction trend between treatment and trial (F6,25 = 2.41, P = 0.056; trial: F6,25 = 5.40, P = 0.001; treatment: F1,30 = 2.41, P = 0.131): initially, there remained a significant difference between treatments, but this difference became nonsignificant as the postshift phase progressed (Fig. 1).
As the LTED-I phase progressed MAPK levels fell, but after 90 weeks remained 30% higher compared to wt MCF-7.
